Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis

British Journal of Dermatology

Volumn 156, Issue 1, 2007, Pages 138-142

  Elewski, B ^a   Leonardi, C ^b   Gottlieb, A B ^c   Strober, B E ^d   Simiens, M A ^e   Dunn, M ^e   Jahreis, A ^e  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

^c TUFTS MEDICAL CENTER   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AMGEN INC   (United States)

Author keywords

Clinical trials; Efficacy; Etanercept; Pharmacokinetics; Psoriasis; Safety

Indexed keywords

ETANERCEPT;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOLOGY LIFE QUALITY INDEX; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OPPORTUNISTIC INFECTION; PHASE 3 CLINICAL TRIAL; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCORING SYSTEM; STEADY STATE; TUBERCULOSIS; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOGLOBULIN G; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33845529288     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2006.07585.x     Document Type: Article

References (8)

1. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46:1-23; quiz 23-6.
2. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 113:1664-75.
3. Krueger G, Koo J, Lebwohl M et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001; 137:280-4.
4. Stern RS, Nijsten T, Feldman SR et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 2004; 9:136-9.
5. Enbrel® (etanercept). Package Insert. Thousand Oaks, CA: Amgen Inc. and Wyeth-Ayerst Pharmaceuticals, 2004.
6. Leonardi CL, Powers JL, Matheson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
7. Papp KA, Tyring S, Lahfa M et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152:1304-12.
8. Keystone EC, Schiff MH, Kremer JM et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004; 50:353-63.